Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$1.11 - $3.46 $43,179 - $134,594
38,900 Added 91.87%
81,241 $118,000
Q1 2022

May 16, 2022

BUY
$1.78 - $8.5 $53,472 - $255,348
30,041 Added 244.24%
42,341 $159,000
Q4 2021

Feb 14, 2022

BUY
$7.3 - $11.24 $89,790 - $138,252
12,300 New
12,300 $96,000

Others Institutions Holding SABS

About SAB Biotherapeutics, Inc.


  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $133M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.